A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: Implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia

Journal of Clinical Psychiatry

Volumn 73, Issue 8, 2012, Pages 1147-1152

  Ikai, Saeko ^a   Remington, Gary ^i,j   Suzuki, Takefumi ^a,b   Takeuchi, Hiroyoshi ^a,c,f   Tsuboi, Takashi ^a,d,f   Den, Ryosuke ^e   Hirano, Jinichi ^a,c,f   Tsunoda, Kenichi ^g   Nishimoto, Masahiko ^h   Watanabe, Koichiro ^a,c   Mimura, Masaru ^a   Mamo, David ^i,j   Uchida, Hiroyuki ^a,f,i  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Inokashira Hospital   (Japan)

^c Ohizumi Hospital   (Japan)

^d Ohizumi Mental Clinic   (Japan)

^e Komagino Hospital   (Japan)

^f Asakadai Mental Clinic   (Japan)

^g Minamihanno Hospital   (Japan)

^h Toyoko Keiai Hospital   (Japan)

ⁱ CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; LEVOMEPROMAZINE; LONG ACTING DRUG; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SULPIRIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

EID: 84865731900     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m07638     Document Type: Article

References (35)

1. Uchida H, Suzuki T, Mamo DC, et al. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry. 2008;16(7): 584-593. doi:10.1097/JGP.0b013e318172b42d PubMed
2. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2, suppl):1-56.
3. Uchida H, Suzuki T, Takeuchi H, et al. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull. 2011;37(4):788-799. doi:10.1093/schbul/sbp149 PubMed
4. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006;67(suppl 5):15-18. PubMed
5. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1-3):83-92. doi:10.1016/j.schres. 2010.1.020 PubMed
6. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry. 2006;67(suppl 5):9-14. PubMed
7. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125-1132. doi:10.176/api.ajp.160.6. 125 PubMed
8. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64(10):1250-1257. doi:10.408/JCP.v64n1017 PubMed
9. Parellada E, Kouniakis F, Siurkute A, et al. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. Int Clin Psychopharmacol. 2010;25(3):149-154. doi:10.1097/YIC.0b013e32836c93f PubMed
10. 2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1081-1090. doi:10.1016/j.pnpbp.203.09.04 PubMed
11. 2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data [published online ahead of print January 30, 2012]. Schizophr Bull. PubMed
12. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-520. doi:10.176/api.ajp.157.4.514 PubMed
13. 2 receptors: a PET study in schizophrenia. Am J Psychiatry. 2007; 164(4):630-637. doi:10.176/api.ajp.164.4.630 PubMed
14. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-235. doi:10.1056/NEJMoa080694 PubMed
15. 2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry. 2008;69(8):1281-1286. doi:10.408/JCP.v69n081 PubMed
16. 2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006;163(3):396-401. doi:10.176/api.ajp.163.3.396 PubMed
17. 2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31(3):318-325. doi:10.1097/JCP.0b013e318218d39 PubMed
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
19. Inagaki A, Inada T, Fujii Y. Dose Equivalents of Psychotropic Drugs [in Japanese]. Tokyo, Japan: Seiwa Press; 1999.
20. Overall JEGD. The Brief Psychiatric Rating Scale. Psychol Rep. 1962; 10(3):799-812. doi:10.246/pr0.1962.10.3.79
21. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(S212):11-19. doi:10.1/j.160-047.1970.tb0206. x PubMed
22. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676. doi:10.192/bjp.154.5.672 PubMed
23. Guy W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC: US Department of Health, Education, and Welfare; 1976.
24. Castberg I, Spigset O. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. Ther Drug Monit. 2005;27(1):103-106. doi:10.1097/07691-205020-019 PubMed
25. Remington G, Seeman P, Feingold A, et al. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(8):1042-1048. doi:10.408/JCP.09m0586yel PubMed
26. 2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(1):182-187. doi:10.1016/j.pnpbp.201.12.013 PubMed
27. Gaebel W, Jänner M, Frommann N, et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res. 2002;53(1-2):145-159. doi:10.1016/S0920-964(01)0182-7 PubMed
28. Gaebel W. Intermittent medication - an alternative? Acta Psychiatr Scand suppl. 1994;89(s382):33-38. doi:10.1/j.160-047.194.tb05863.x PubMed
29. Jolley AG, Hirsch SR, McRink A, et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ. 1989;298(6679):985-990. doi:10.136/bmj.298.679.985 PubMed
30. 2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31(4):497-502. doi:10.1097/JCP. 0b013e318214ad PubMed
31. Turrone P, Remington G, Kapur S, et al. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry. 2005;57(4):406-411. doi:10.1016/j.biopsych.204.10.023 PubMed
32. 2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int J Neuropsychopharmacol. 2009;12(5):715-721. doi:10.1017/S1461457090327 PubMed
33. Boulougouris V, Tsaltas E. Serotonergic and dopaminergic modulation of attentional processes. Prog Brain Res. 2008;172:517-542. doi:10.1016/S079- 6123(08)0925-4 PubMed
34. González-Burgos I, Feria-Velasco A. Serotonin/dopamine interaction in memory formation. Prog Brain Res. 2008;172:603-623. doi:10.1016/S079- 6123(08)0928-X PubMed
35. Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60(2):198-203.